A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

The fall comes amid European regulators rejecting its Alzheimer’s drug Kisunla over safety concerns, while Medicare remains undecided on obesity drug coverage—putting Lilly and rival Novo Nordisk in .

diabetes, and other serious chronic illnesses. Indeed, CEO Lars Fruergaard Jorgensen said that Brazil plays a key role in Novo Nordisk’s global plans and that the company exports to over 70 ...

The investment aims to increase manufacturing capacity at Novo Nordisk's facility in Minas Gerais state for injectable drugs for the treatment of obesity, diabetes and other serious chronic diseases, ...

The investment aims to increase manufacturing capacity at Novo Nordisk's facility in Minas Gerais state for injectable drugs for the treatment of obesity, diabetes and other serious chronic ...

A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes and obesity medications ... of the now-famous drugs manufactured by Novo ...

A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes and ... drugs manufactured by Novo Nordisk and Eli Lilly.

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals ... to reduce the risk of major adverse cardiovascular events in adults with Type 2 diabetes who also have atherosclerotic ...

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory. Investors ...